(159 days)
Not Found
No
The 510(k) summary describes a bone substitute material and its physical properties and performance in bench and animal studies. There is no mention of AI or ML in the intended use, device description, or performance studies.
Yes
The device is a bone substitute material intended to fill bony voids and aid in supporting bone fragments, which directly treats anatomical defects created by trauma or surgery in the skeletal system.
No
The device is a bone substitute cement used to fill bony voids or gaps; it does not analyze or interpret physiological data to diagnose a condition.
No
The device description clearly states it is a calcium phosphate cement provided in powder form and packaged in a mixing syringe, indicating it is a physical material and not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is used to fill bony voids or gaps in the skeletal system. This is a therapeutic and structural application within the body.
- Device Description: The description details a bone substitute material that is injected and sets in situ. This is a material implanted into the body.
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body (like blood, urine, or tissue) to detect diseases, conditions, or infections. This device does not perform any such testing.
The device is a medical device used for surgical intervention and bone repair, not for diagnostic testing of biological samples.
N/A
Intended Use / Indications for Use
DSM Biomedical Calcium Phosphate Cement is indicated to fill bony voids or gaps of the skeletal system (i.e. extremities and pelvis). These defects may be surgically created or osseous defects created from traumatic injury to the bone. The DSM Biomedical Calcium Phosphate Cement is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. The DSM Biomedical Calcium Phosphate Cement cured in situ provides an open void/gap filler that can augment provisional hardware (e.g. K-Wires, plates, screws) to help support bone fragments during the surgical procedure. The cured cement acts only as a temporary support media and is not intended to provide structural support during the healing process. The Calcium Phosphate Cement resorbs and is replaced by bone during the healing process.
Product codes (comma separated list FDA assigned to the subject device)
MQV, OIS
Device Description
DSM Biomedical Calcium Phosphate Cement as an injectable, fast self-setting bone substitute. DSM Biomedical Calcium Phosphate Cement is composed of calcium phosphate which converts to hydroxyapatite in vivo, and bovine collagen powder. The device can also be used to augment provisional hardware to help support bone fragments during the surgical procedure. The cement is provided in a powder form packaged in a mixing syringe. The mixing syringe allows for the combination of saline, the patient's blood, or the patient's bone marrow at the required powder-to-liquid ratio. DSM Biomedical Calcium Phosphate Cement is supplied sterile by gamma irradiation and is non-pyrogenic.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
skeletal system (i.e. extremities and pelvis)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Material characterization, including chemical and material physical characterization, bench testing, biocompatibility testing, viral inactivation, and an animal study have been conducted to evaluate the performance characteristics and biological safety of DSM Biomedical Calcium Phosphate Cement.
Material characterization and performance testing of the DSM Biomedical Calcium Phosphate Cement was completed in accordance with the FDA Guidance Document, Resorbable Calcium Salt Bone Void Filler Device and ASTM F1185 Standard Specification for Composition of Hydroxylapatite for Surgical Implants.
An ovine bilateral femoral defect animal study was performed to evaluate bone healing following treatment with the DSM Biomedical Calcium Phosphate Cement compared to the predicate device.
Biocompatibility testing was completed in accordance with the requirements of ISO 10993-1: 2009, Biological Evaluation of Medical Devices—Part 1: Evaluation and Testing within a Risk Management Process for a permanent implant device with tissue/bone contact. Testing included cytotoxicity, sensitization, irritation, acute systemic toxicity, genotoxicity, hemocompatibility, subacute toxicity, and implantation. Other safety testing included a viral inactivation study and residual chemical assessment. Results indicate that the device's biocompatibility profile is acceptable.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3045 Resorbable calcium salt bone void filler device.
(a)
Identification. A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.
0
Image /page/0/Picture/0 description: The image shows the logos of the Department of Health & Human Services and the U.S. Food & Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo includes the letters "FDA" in a blue square, followed by the words "U.S. Food & Drug Administration" in blue text. The word "Administration" is on the second line.
Kensey Nash Corporation dba DSM Biomedical Susan Pileggi Senior Regulatory Specialist 735 Pennsylvania Drive Exton, Pennsylvania 19431
April 3, 2018
Re: K173362
Trade/Device Name: DSM Biomedical Calcium Phosphate Cement Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable calcium salt bone void filler device Regulatory Class: Class II Product Code: MQV, OIS Dated: February 26, 2018 Received: February 28, 2018
Dear Ms. Pileggi:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);
1
and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Mark N. Melkerson -S
Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Form Approved: OMB No. 0910-0120
Expiration Date: 06/30/2020
See PRA Statement below.
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) K173362
Device Name DSM Biomedical Calcium Phosphate Cement
Indications for Use (Describe)
DSM Biomedical Calcium Phosphate Cement is indicated to fill bony voids or gaps of the skeletal system (i.e. extremities and pelvis). These defects may be surgically created or osseous defects created from traumatic injury to the bone. The DSM Biomedical Calcium Phosphate Cement is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. The DSM Biomedical Calcium Phosphate Cement cured in situ provides an open void/gap filler that can augment provisional hardware (e.g. K-Wires, plates, screws) to help support bone fragments during the surgical procedure. The cured cement acts only as a temporary support media and is not intended to provide structural support during the healing process. The Calcium Phosphate Cement resorbs and is replaced by bone during the healing process.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows the logo for DSM, a global science-based company active in health, nutrition, and materials. The logo consists of a colorful abstract graphic on the left and the letters "DSM" in bold blue font on the right. The graphic is composed of overlapping, translucent shapes in various colors, including blue, green, orange, and purple, creating a sense of dynamism and innovation.
510(k) Summary
| Submitted By: | DSM Biomedical
735 Pennsylvania Drive
Exton, PA 19341 |
|-----------------|--------------------------------------------------------------------------------|
| Contact Person: | Susan Pileggi
susan.pileggi@dsm.com
(P) 484-713-2100
(F) 484-713-2903 |
| Date Prepared: | February 23, 2018 |
Device:
| Trade Name: | DSM Biomedical Calcium Phosphate Cement |
|---|---|
| Common/Usual Name: | Bone Void Filler |
| Classification Name: | Resorbable Calcium Salt Bone Void Filler Device |
| Classification Regulation: | 21 CFR 880.3045 |
| Device Class: | II |
| Device Code: | MQV: Filler, Bone Void, Calcium Compound |
| OIS: Calcium Salt Bone Void Filler, Drillable, Non-screw Augmentation | |
| Advisory Panel: | Orthopedic |
Predicate Device: Stryker® Injectable Cement (K060061) [Stryker® CMF]
Device Description
DSM Biomedical Calcium Phosphate Cement as an injectable, fast self-setting bone substitute. DSM Biomedical Calcium Phosphate Cement is composed of calcium phosphate which converts to hydroxyapatite in vivo, and bovine collagen powder. The device can also be used to augment provisional hardware to help support bone fragments during the surgical procedure. The cement is provided in a powder form packaged in a mixing syringe. The mixing syringe allows for the combination of saline, the patient's blood, or the patient's bone marrow at the required powder-to-liquid ratio. DSM Biomedical Calcium Phosphate Cement is supplied sterile by gamma irradiation and is non-pyrogenic.
4
Image /page/4/Picture/0 description: The image shows the logo for DSM, a global science-based company. The logo consists of a colorful abstract graphic on the left and the letters "DSM" in bold blue font on the right. The graphic is composed of overlapping curved shapes in various colors, including blue, green, purple, and orange. The overall design is modern and corporate.
Indications For Use:
DSM Biomedical Calcium Phosphate Cement is indicated to fill bony voids or gaps of the sketal system (i.e. extremities and pelvis). These defects may be surgically created or osseous defects created from traumatic injury to the bone. The Calcium Phosphate Cement is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. The Calcium Phosphate Cement cured in situ provides an open void/gap filler that can augment provisional hardware (e.g. K-Wires, plates, screws) to help support bone fragments during the surgical procedure. The cured cement acts only as a temporary support media and is not intended to provide structural support during the healing process. The Calcium Phosphate Cement resorbs and is replaced by bone during the healing process.
Basis for Substantial Equivalence:
The DSM Biomedical Calcium Phosphate Cement is substantially equivalent in terms of indications for use, material composition, technological characteristics and performance characteristics to that of the predicate device, Stryker® Injectable Cement (K060061).
DSM Biomedical Calcium Phosphate Cement and the predicate device have comparable indications for use. Both are calcium phosphate powders that when mixed with a mixing liquid form a fast setting cement. The addition of the collagen to the subject device does not raise questions of substantial equivalence as the safety of the collagen has been shown through biocompatibility, an animal study, and a viral inactivation The subject and predicate devices are both injectable, and fast setting calcium study. phosphate cement that converts to hydroxyapatite over time. Both the subject and predicate devices are packaged with accessories to aid in the mixing and delivery of the subject and predicate devices are provided sterile and are for single use only. The subject and predicate devices are biocompatible and non-pyrogenic.
5
Image /page/5/Picture/0 description: The image shows the DSM company logo. The logo consists of a colorful abstract design on the left and the letters "DSM" in blue on the right. The abstract design is made up of overlapping shapes in various colors, including blue, green, yellow, and purple. The letters "DSM" are in a bold, sans-serif font.
| Charactestic | DSM Biomedical Calcium Phosphate
Cement (Proposed) | Stryker® Injectable Cement
(K060061) |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications For
Use | DSM Biomedical Calcium Phosphate
Cement is indicated to fill bony voids or
gaps of the skeletal system (i.e.
extremities and pelvis). These defects
may be surgically created or osseous
defects created from traumatic injury
to the bone. The Calcium Phosphate
Cement is indicated only for bony voids
or gaps that are not intrinsic to the
stability of the bony structure. The
Calcium Phosphate Cement cured in situ
provides an open void/gap filler that
can augment provisional hardware (e.g.
K-Wires, plates, screws) to help support
bone fragments during the surgical
procedure. The cured cement acts only
as a temporary support media and is not
intended to provide structural support
during the healing process. The
Calcium Phosphate Cement resorbs and
is replaced by bone during the healing
process. | Stryker Injectable Cement is a self-setting
calcium phosphate cement indicated to fill
bony voids or gaps of the skeletal system
(i.e. extremities, craniofacial, spine, and
pelvis.) These defects may be surgically
created or osseous defects created from
traumatic injury to the bone. The Stryker
Injectable Cement is indicated only for
bony voids or gaps that are not intrinsic to
the stability of the bony structure. Stryker
Injectable Cement cured in situ provides an open
void/gap filler that can augment
provisional hardware (e.g. K-Wires,plates,
screws) to help support bone fragments
during the surgical procedure. The cured
cement acts only as a temporary support
media and is not intended to provide
structural support during the healing
process. |
| Material | Calcium phosphate powder with bovine
collagen mixed with saline, patient's
blood, or patient's bone marrow to form
hydroxyapatite | Calcium phosphate powder mixed with
mixing liquid to form hydroxyapatite |
| Form | Injectable, sculptable, and fast setting
calcium phosphate cement that
converts to hydroxyapatite | Injectable, sculptable, and fast setting
calcium phosphate cement that converts to
hydroxyapatite |
| Packaging | Powder prepackaged in a mixing and
delivery syringe, packaged with
accessories to aid in the mixing and
delivery of cement | Calcium phosphate powder in a bowl,
packaged with accessories to aid in the
mixing and delivery of the cement |
| Sterilization | Sterile, SAL 10-6 | Sterile, SAL 10-6 |
| Reusable | Single Use Device | Single Use Device |
| Biocompatible | Yes | Yes |
Performance Data:
Material characterization, including chemical and material physical characterization, bench testing, biocompatibility testing, viral inactivation, and an animal study have been conducted to evaluate the performance characteristics and biological safety of DSM Biomedical Calcium Phosphate Cement.
6
Image /page/6/Picture/0 description: The image shows the logo for DSM, a global science-based company active in health, nutrition, and materials. The logo consists of a colorful abstract graphic on the left and the letters "DSM" in bold blue font on the right. The graphic is composed of overlapping shapes in various colors, including blue, green, purple, and orange, forming a circular design with a hexagonal shape in the center.
Material characterization and performance testing of the DSM Biomedical Calcium Phosphate Cement was completed in accordance with the FDA Guidance Document, Resorbable Calcium Salt Bone Void Filler Device and ASTM F1185 Standard Specification for Composition of Hydroxylapatite for Surgical Implants.
An ovine bilateral femoral defect animal study was performed to evaluate bone healing following treatment with the DSM Biomedical Calcium Phosphate Cement compared to the predicate device.
Biocompatibility testing was completed in accordance with the requirements of ISO 10993-1: 2009, Biological Evaluation of Medical Devices—Part 1: Evaluation and Testing within a Risk Management Process for a permanent implant device with tissue/bone contact. Testing included cytotoxicity, sensitization, irritation, acute systemic toxicity, genotoxicity, hemocompatibility, subacute toxicity, and implantation. Other safety testing included a viral inactivation study and residual chemical assessment. Results indicate that the device's biocompatibility profile is acceptable.
Substantial Equivalence:
DSM Biomedical Calcium Phosphate Cement has the same intended use and similar indications, technological characteristics, and principles of operation as the predicate device. The minor technological differences that exist between the DSM Biomedical Calcium Phosphate Cement do not raise any new issues of safety and effectiveness. The bench, animal, and biocompatibility testing demonstrates that DSM Biomedical Calcium Phosphate Cement is substantially equivalent to the predicate device.
Conclusion:
The DSM Biomedical Calcium Phosphate Cement is substantially equivalent in terms of indications for use, material composition, technological characteristics, and performance characteristics to the predicate device, Stryker® Injectable Cement (K060061) [Stryker® CMF].